\-\ Texto\\:\\ \ \(0\)\
\-\ normal\\ heart\\ size\\.\\ linear\\ interstitial\\ pattern\\ in\\ bilateral\\ bases\\ with\\ bilateral\\ blunting\\ of\\ the\\ costophrenic\\ angles\\.\\ flattening\\ of\\ the\\ hemidiaphragms\\.\\ pleural\\ thickening\\.\\ minor\\ fissure\\ visualized\\ on\\ pa\\.\\ bones\\ and\\ soft\\ tissues\\ are\\ unremarkable\\.\ \(0\)\
\-\ chronic\\ interstitial\\ lung\\ disease\\ secondary\\ to\\ sle\ \(0\)\
\-\ the\\ patient\\ is\\ a\\ 55yo\\ african\\ american\\ female\\ with\\ a\\ 30\\ year\\ history\\ of\\ sle\\ manifested\\ by\\ proteinuria\\,\\ jaccoud\\'s\\ arthritis\\,\\ h\\/o\\ cns\\ vasculitis\\,\\ discoid\\ lesions\\,\\ and\\ chronic\\ interstitial\\ lung\\ disease\\ who\\ presented\\ with\\ a\\ non\\-productive\\ cough\\,\\ clear\\ rhinorrhea\\,\\ and\\ an\\ increase\\ in\\ her\\ home\\ oxygen\\ requirement\\ from\\ 2lnc\\ to\\ 3lnc\\.\\ pt\\ complained\\ of\\ shortness\\ of\\ breath\\ without\\ chest\\ pain\\ that\\ progressed\\ over\\ three\\ days\\ prior\\ to\\ admission\\.\\ pt\\ reported\\ that\\ she\\ increased\\ her\\ use\\ of\\ her\\ albuterol\\ inhaler\\ with\\ minimal\\ relief\\ of\\ her\\ dyspnea\\.\\ pt\\ denied\\ any\\ fevers\\,\\ chills\\,\\ night\\ sweats\\,\\ nausea\\,\\ vomiting\\,\\ or\\ diarrhea\\.\\ pt\\ was\\ afebrile\\ and\\ her\\ wbc\\ was\\ wnl\\.\\ pt\\ was\\ on\\ prednisone\\ chronically\\.\ \(0\)\
\-\ systemic\\ lupus\\ erythematosus\\ is\\ an\\ autoimmune\\ disease\\ with\\ a\\ peak\\ incidence\\ in\\ females\\ between\\ the\\ ages\\ of\\ 15\\ and\\ 40\\.\\ the\\ female\\ to\\ male\\ ratio\\ is\\ about\\ 5\\:1\\.\\ in\\ the\\ united\\ states\\,\\ sle\\ is\\ more\\ prevalent\\ among\\ blacks\\ and\\ hispanics\\.\\ sle\\ occurs\\ with\\ a\\ much\\ higher\\ frequency\\ among\\ first\\ degree\\ relatives\\.\\ also\\,\\ within\\ extended\\ families\\ other\\ autoimmune\\ conditions\\ such\\ as\\ hemolytic\\ anemia\\,\\ idiopathic\\ thrombocytopenia\\ purpura\\,\\ and\\ thyroiditis\\ may\\ be\\ found\\ in\\ addition\\ to\\ sle\\.\\ although\\ sle\\ demonstrates\\ a\\ hereditary\\ influence\\,\\ most\\ cases\\ of\\ sle\\ are\\ sporadic\\ and\\ idiopathic\\.\ \(0\)\
\-\ pulmonary\\ disease\\ is\\ a\\ relatively\\ common\\ manifestation\\ of\\ sle\\.\\ however\\,\\ the\\ specific\\ clinical\\ manifestations\\ of\\ sle\\ involvement\\ of\\ the\\ respiratory\\ system\\ are\\ very\\ diverse\\.\\ these\\ manifestations\\ include\\ acute\\ lupus\\ pneumonitis\\,\\ chronic\\ interstitial\\ lung\\ disease\\,\\ pulmonary\\ hemorrhage\\,\\ pulmonary\\ embolism\\,\\ pulmonary\\ hypertension\\,\\ and\\ shrinking\\ lung\\ syndrome\\.\\ lupus\\ pneumonitis\\ can\\ present\\ as\\ an\\ acute\\ illness\\ or\\ as\\ a\\ chronic\\ process\\.\ \(0\)\
\-\ acute\\ lupus\\ pneumonitis\\ is\\ uncommon\\.\\ it\\ presents\\ with\\ the\\ same\\ signs\\ and\\ symptoms\\ as\\ an\\ infectious\\ pneumonia\\;\\ cough\\,\\ fever\\,\\ dyspnea\\,\\ patchy\\ alveolar\\ infiltrates\\ on\\ chest\\ \\.radiography\\,\\ and\\ occasionally\\ hemoptysis\\ with\\ a\\ drop\\ in\\ hematocrit\\.\\ often\\ the\\ acute\\ lupus\\ pulmonary\\ disease\\ is\\ accompanied\\ by\\ other\\ signs\\ of\\ sle\\ exacerbation\\.\\ when\\ there\\ is\\ a\\ doubt\\ as\\ to\\ the\\ etiology\\ of\\ the\\ pulmonary\\ infiltrates\\,\\ a\\ bronchoalveolar\\ lavage\\ is\\ indicated\\.\\ the\\ accepted\\ first\\ line\\ treatment\\ is\\ glucocorticoids\\.\\ when\\ hemoptysis\\ is\\ present\\,\\ it\\ is\\ thought\\ to\\ be\\ the\\ result\\ of\\ pulmonary\\ hemorrhage\\ due\\ to\\ pulmonary\\ vasculitis\\.\\ for\\ the\\ pulmonary\\ hemorrhage\\ syndromes\\ of\\ acute\\ immune\\-mediated\\ lung\\ injury\\ in\\ sle\\ patients\\,\\ pulse\\ methylprednisone\\ therapy\\ may\\ be\\ effective\\.\\ for\\ critically\\ ill\\ patients\\,\\ the\\ addition\\ of\\ azathioprine\\ or\\ cyclophosphamide\\ to\\ the\\ glucocorticoids\\ is\\ recommended\\.\\ the\\ reported\\ overall\\ mortality\\ rate\\ for\\ acute\\ lupus\\ pneumonitis\\ is\\ over\\ 50\\%\\ despite\\ treatment\\.\ \(0\)\
\-\ the\\ chronic\\ form\\ of\\ lupus\\ pneumonitis\\ can\\ result\\ as\\ a\\ consequence\\ of\\ previous\\ insult\\ to\\ the\\ lungs\\ from\\ acute\\ pneumonitis\\ or\\ can\\ be\\ an\\ independent\\ manifestation\\ of\\ sle\\.\\ it\\ is\\ characterized\\ by\\ exertional\\ dyspnea\\,\\ non\\-productive\\ cough\\,\\ basilar\\ rales\\,\\ and\\ radiographic\\ findings\\ consistent\\ with\\ interstitial\\ lung\\ disease\\.\\ often\\ radiographic\\ findings\\ of\\ interstitial\\ lung\\ disease\\ may\\ be\\ noted\\ prior\\ to\\ clinical\\ symptoms\\ being\\ manifested\\.\\ the\\ major\\ clinical\\ question\\ that\\ must\\ be\\ addressed\\ in\\ chronic\\ lupus\\ pneumonitis\\ is\\ whether\\ inflammatory\\ alveolitis\\ present\\.\\ inflammatory\\ alveolitis\\ can\\ be\\ treated\\ with\\ immunosuppression\\ where\\ as\\ chronic\\ fibrosis\\ is\\ not\\ treatable\\.\\ discriminating\\ between\\ inflammatory\\ alveolitis\\ and\\ chronic\\ fibrosis\\ can\\ be\\ difficult\\.\\ a\\ reticular\\ pattern\\ with\\ honeycombing\\ on\\ high\\ resolution\\ ct\\ is\\ suggestive\\ of\\ irreversible\\ fibrosis\\.\\ a\\ ground\\-glass\\ appearance\\ is\\ indicative\\ of\\ active\\ inflammation\\ on\\ high\\ resolution\\ ct\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ sle\\:\\ 0\\.09656680802389005\ \(0\)\
\-\ lupus\\:\\ 0\\.06348679861259604\ \(0\)\
\-\ pneumonitis\\:\\ 0\\.06271320103511269\ \(0\)\
\-\ interstitial\\:\\ 0\\.03956583062211542\ \(0\)\
\-\ pulmonary\\:\\ 0\\.035439988630884184\ \(0\)\
\-\ alveolitis\\:\\ 0\\.033235452467216604\ \(0\)\
\-\ chronic\\:\\ 0\\.030372108932580442\ \(0\)\
\-\ lung\\:\\ 0\\.0273282552707748\ \(0\)\
\-\ pt\\:\\ 0\\.025056496487640002\ \(0\)\
\-\ acute\\:\\ 0\\.02329519763997708\ \(0\)\
\-\ manifested\\:\\ 0\\.020877898569811603\ \(0\)\
\-\ non\\-productive\\:\\ 0\\.020545531012531395\ \(0\)\
\-\ her\\:\\ 0\\.020263498883950595\ \(0\)\
\-\ glucocorticoids\\:\\ 0\\.01948410439858435\ \(0\)\
\-\ dyspnea\\:\\ 0\\.01913959211120268\ \(0\)\
\-\ fibrosis\\:\\ 0\\.018004178847966446\ \(0\)\
\-\ disease\\:\\ 0\\.01762444846959879\ \(0\)\
\-\ manifestation\\:\\ 0\\.017412244662341227\ \(0\)\
\-\ autoimmune\\:\\ 0\\.017186822063028465\ \(0\)\
\-\ is\\:\\ 0\\.016850985472097457\ \(0\)\
\-\ infiltrates\\:\\ 0\\.016779214077287122\ \(0\)\
\-\ be\\:\\ 0\\.016627845089513302\ \(0\)\
\-\ among\\:\\ 0\\.016018450491113972\ \(0\)\
\-\ hemoptysis\\:\\ 0\\.015532170744024831\ \(0\)\
\-\ cough\\:\\ 0\\.015493319615811067\ \(0\)\
\-\ manifestations\\:\\ 0\\.015344715158943438\ \(0\)\
\-\ can\\:\\ 0\\.015285665240292345\ \(0\)\
\-\ as\\:\\ 0\\.014271360475171758\ \(0\)\
\-\ \\,\\:\\ 0\\.014090587006420323\ \(0\)\
\-\ inflammatory\\:\\ 0\\.014021999735924403\ \(0\)\
\-\ 55yo\\:\\ 0\\.01390460319237618\ \(0\)\
\-\ jaccoud\\:\\ 0\\.01390460319237618\ \(0\)\
\-\ 2lnc\\:\\ 0\\.01390460319237618\ \(0\)\
\-\ 3lnc\\:\\ 0\\.01390460319237618\ \(0\)\
\-\ hispanics\\:\\ 0\\.01390460319237618\ \(0\)\
\-\ \\.radiography\\:\\ 0\\.01390460319237618\ \(0\)\
\-\ vasculitis\\:\\ 0\\.01379453365134442\ \(0\)\
\-\ hemorrhage\\:\\ 0\\.01345862736991815\ \(0\)\
\-\ diverse\\:\\ 0\\.012811311109474057\ \(0\)\
\-\ immune\\-mediated\\:\\ 0\\.012811311109474057\ \(0\)\
\-\ methylprednisone\\:\\ 0\\.012811311109474057\ \(0\)\
\-\ discriminating\\:\\ 0\\.012811311109474057\ \(0\)\
\-\ clinical\\:\\ 0\\.012441529022394341\ \(0\)\
\-\ idiopathic\\:\\ 0\\.012288761823780357\ \(0\)\
\-\ discoid\\:\\ 0\\.012171776238640991\ \(0\)\
\-\ inhaler\\:\\ 0\\.012171776238640991\ \(0\)\
\-\ 5\\:1\\.\\:\\ 0\\.012171776238640991\ \(0\)\
\-\ families\\:\\ 0\\.011718019026571935\ \(0\)\
\-\ shrinking\\:\\ 0\\.011718019026571935\ \(0\)\
\-\ critically\\:\\ 0\\.011718019026571935\ \(0\)\
\-\ resolution\\:\\ 0\\.011626560596351497\ \(0\)\
\-\ addition\\:\\ 0\\.011427639031786396\ \(0\)\
\-\ 40\\.\\:\\ 0\\.01136605758916782\ \(0\)\
\-\ relatives\\:\\ 0\\.01136605758916782\ \(0\)\
\-\ independent\\:\\ 0\\.01136605758916782\ \(0\)\
\-\ blacks\\:\\ 0\\.01107848415573887\ \(0\)\
\-\ influence\\:\\ 0\\.01107848415573887\ \(0\)\
\-\ treatable\\:\\ 0\\.01107848415573887\ \(0\)\
\-\ doubt\\:\\ 0\\.010835344282194298\ \(0\)\
\-\ azathioprine\\:\\ 0\\.010835344282194298\ \(0\)\
\-\ immunosuppression\\:\\ 0\\.010835344282194298\ \(0\)\
\-\ irreversible\\:\\ 0\\.010624726943669813\ \(0\)\
\-\ hemidiaphragms\\:\\ 0\\.010438949284905802\ \(0\)\
\-\ accepted\\:\\ 0\\.010438949284905802\ \(0\)\
\-\ exertional\\:\\ 0\\.010438949284905802\ \(0\)\
\-\ result\\:\\ 0\\.010341274943053506\ \(0\)\
\-\ pattern\\:\\ 0\\.010304234508111288\ \(0\)\
\-\ requirement\\:\\ 0\\.010272765506265697\ \(0\)\
\-\ chronically\\:\\ 0\\.010272765506265697\ \(0\)\
\-\ thrombocytopenia\\:\\ 0\\.010272765506265697\ \(0\)\
\-\ purpura\\:\\ 0\\.010272765506265697\ \(0\)\
\-\ addressed\\:\\ 0\\.010272765506265697\ \(0\)\
\-\ radiographic\\:\\ 0\\.010231433412582756\ \(0\)\
\-\ rhinorrhea\\:\\ 0\\.01012243399237875\ \(0\)\
\-\ prevalent\\:\\ 0\\.01012243399237875\ \(0\)\
\-\ consequence\\:\\ 0\\.01012243399237875\ \(0\)\
\-\ proteinuria\\:\\ 0\\.009985192072836747\ \(0\)\
\-\ albuterol\\:\\ 0\\.009985192072836747\ \(0\)\
\-\ hemolytic\\:\\ 0\\.009985192072836747\ \(0\)\
\-\ honeycombing\\:\\ 0\\.009985192072836747\ \(0\)\
\-\ insult\\:\\ 0\\.009858941745275964\ \(0\)\
\-\ reported\\:\\ 0\\.009826734544403191\ \(0\)\
\-\ lavage\\:\\ 0\\.009742052199292176\ \(0\)\
\-\ cyclophosphamide\\:\\ 0\\.009742052199292176\ \(0\)\
\-\ bronchoalveolar\\:\\ 0\\.00963323063543263\ \(0\)\
\-\ ground\\-glass\\:\\ 0\\.00963323063543263\ \(0\)\
\-\ signs\\:\\ 0\\.009486990328031717\ \(0\)\
\-\ angles\\:\\ 0\\.009345657202003681\ \(0\)\
\-\ an\\:\\ 0\\.009319123535368531\ \(0\)\
\-\ erythematosus\\:\\ 0\\.009179473423363576\ \(0\)\
\-\ present\\:\\ 0\\.009132533535954326\ \(0\)\
\-\ it\\:\\ 0\\.009089187939430678\ \(0\)\
\-\ first\\:\\ 0\\.009045689068725086\ \(0\)\
\-\ blunting\\:\\ 0\\.009029141909476629\ \(0\)\
\-\ may\\:\\ 0\\.008869061682483236\ \(0\)\
\-\ costophrenic\\:\\ 0\\.00882751198595946\ \(0\)\
\-\ ill\\:\\ 0\\.008765649662373842\ \(0\)\
\-\ reticular\\:\\ 0\\.008765649662373842\ \(0\)\
\-\ a\\:\\ 0\\.008757724330379208\ \(0\)\
\-\ sporadic\\:\\ 0\\.008706122331170614\ \(0\)\
\-\ often\\:\\ 0\\.008600862929084076\ \(0\)\
\-\ between\\:\\ 0\\.008544149956543356\ \(0\)\
\-\ thyroiditis\\:\\ 0\\.008488219589087305\ \(0\)\
\-\ exacerbation\\:\\ 0\\.008389607038643561\ \(0\)\
\-\ united\\:\\ 0\\.008296798678985938\ \(0\)\
\-\ drop\\:\\ 0\\.008296798678985938\ \(0\)\
\-\ accompanied\\:\\ 0\\.008296798678985938\ \(0\)\
\-\ alveolar\\:\\ 0\\.008047234001990837\ \(0\)\
\-\ prednisone\\:\\ 0\\.007972110896329552\ \(0\)\
\-\ hematocrit\\:\\ 0\\.007935849826574505\ \(0\)\
\-\ progressed\\:\\ 0\\.007798607907032504\ \(0\)\
\-\ extended\\:\\ 0\\.007798607907032504\ \(0\)\
\-\ oxygen\\:\\ 0\\.007734219903057337\ \(0\)\
\-\ hereditary\\:\\ 0\\.007734219903057337\ \(0\)\
\-\ question\\:\\ 0\\.007734219903057337\ \(0\)\
\-\ when\\:\\ 0\\.007720287815823361\ \(0\)\
\-\ bases\\:\\ 0\\.007702985475145382\ \(0\)\
\-\ syndromes\\:\\ 0\\.007702985475145382\ \(0\)\
\-\ indicative\\:\\ 0\\.007702985475145382\ \(0\)\
\-\ sweats\\:\\ 0\\.007672357579471719\ \(0\)\
\-\ peak\\:\\ 0\\.007672357579471719\ \(0\)\
\-\ effective\\:\\ 0\\.007672357579471719\ \(0\)\
\-\ ages\\:\\ 0\\.007642313107909112\ \(0\)\
\-\ females\\:\\ 0\\.0075001189486121125\ \(0\)\
\-\ illness\\:\\ 0\\.0075001189486121125\ \(0\)\
\-\ ratio\\:\\ 0\\.0074731561199696825\ \(0\)\
\-\ rales\\:\\ 0\\.007420575015446667\ \(0\)\
\-\ to\\:\\ 0\\.007409699042386197\ \(0\)\
\-\ high\\:\\ 0\\.007377116911914245\ \(0\)\
\-\ flattening\\:\\ 0\\.007344850694963448\ \(0\)\
\-\ mortality\\:\\ 0\\.007344850694963448\ \(0\)\
\-\ whether\\:\\ 0\\.007249228263076327\ \(0\)\
\-\ fissure\\:\\ 0\\.007226201765566622\ \(0\)\
\-\ patchy\\:\\ 0\\.007226201765566622\ \(0\)\
\-\ complained\\:\\ 0\\.007115856988584113\ \(0\)\
\-\ frequency\\:\\ 0\\.007115856988584113\ \(0\)\
\-\ occasionally\\:\\ 0\\.007094685032224272\ \(0\)\
\-\ basilar\\:\\ 0\\.007073793507381967\ \(0\)\
\-\ african\\:\\ 0\\.007032822708638654\ \(0\)\
\-\ h\\/o\\:\\ 0\\.007032822708638654\ \(0\)\
\-\ diarrhea\\:\\ 0\\.006992889257559331\ \(0\)\
\-\ that\\:\\ 0\\.006984135939552792\ \(0\)\
\-\ patients\\:\\ 0\\.006976576023236675\ \(0\)\
\-\ pulse\\:\\ 0\\.006953941919088714\ \(0\)\
\-\ prior\\:\\ 0\\.006921491394960137\ \(0\)\
\-\ minor\\:\\ 0\\.006915933162654864\ \(0\)\
\-\ wnl\\:\\ 0\\.006915933162654864\ \(0\)\
\-\ cns\\:\\ 0\\.00689726682567221\ \(0\)\
\-\ relief\\:\\ 0\\.006878818813427429\ \(0\)\
\-\ over\\:\\ 0\\.006863225836403667\ \(0\)\
\-\ chills\\:\\ 0\\.006738523094158509\ \(0\)\
\-\ by\\:\\ 0\\.0067328276178779565\ \(0\)\
\-\ symptoms\\:\\ 0\\.00671816238769129\ \(0\)\
\-\ conditions\\:\\ 0\\.006705315824130382\ \(0\)\
\-\ anemia\\:\\ 0\\.006705315824130382\ \(0\)\
\-\ overall\\:\\ 0\\.006705315824130382\ \(0\)\
\-\ characterized\\:\\ 0\\.006705315824130382\ \(0\)\
\-\ higher\\:\\ 0\\.006609693392243259\ \(0\)\
\-\ embolism\\:\\ 0\\.006594305103685903\ \(0\)\
\-\ uncommon\\:\\ 0\\.006594305103685903\ \(0\)\
\-\ denied\\:\\ 0\\.006563971725250749\ \(0\)\
\-\ night\\:\\ 0\\.006549021025006989\ \(0\)\
\-\ bilateral\\:\\ 0\\.006542011764398877\ \(0\)\
\-\ chest\\:\\ 0\\.006450249211537914\ \(0\)\
\-\ systemic\\:\\ 0\\.006448155528792046\ \(0\)\
\-\ american\\:\\ 0\\.006420483116093451\ \(0\)\
\-\ home\\:\\ 0\\.00640682686570999\ \(0\)\
\-\ fevers\\:\\ 0\\.00640682686570999\ \(0\)\
\-\ states\\:\\ 0\\.00634026479238132\ \(0\)\
\-\ or\\:\\ 0\\.0063187555139666085\ \(0\)\
\-\ degree\\:\\ 0\\.006314407048255647\ \(0\)\
\-\ form\\:\\ 0\\.006301635423283062\ \(0\)\
\-\ major\\:\\ 0\\.006301635423283062\ \(0\)\
\-\ despite\\:\\ 0\\.006263929554428876\ \(0\)\
\-\ much\\:\\ 0\\.006239283942594363\ \(0\)\
\-\ afebrile\\:\\ 0\\.006227104059165482\ \(0\)\
\-\ other\\:\\ 0\\.006213370816096052\ \(0\)\
\-\ thought\\:\\ 0\\.006203022872839317\ \(0\)\
\-\ incidence\\:\\ 0\\.006179303823368433\ \(0\)\
\-\ must\\:\\ 0\\.0061443809118901785\ \(0\)\
\-\ admission\\:\\ 0\\.005939530625736531\ \(0\)\
\-\ difficult\\:\\ 0\\.00589959717465721\ \(0\)\
\-\ indicated\\:\\ 0\\.0058320577469238855\ \(0\)\
\-\ infectious\\:\\ 0\\.005794723765715833\ \(0\)\
\-\ relatively\\:\\ 0\\.005767291994876923\ \(0\)\
\-\ arthritis\\:\\ 0\\.005758253075777577\ \(0\)\
\-\ suggestive\\:\\ 0\\.005758253075777577\ \(0\)\
\-\ findings\\:\\ 0\\.005737655948864225\ \(0\)\
\-\ inflammation\\:\\ 0\\.005731443018413901\ \(0\)\
\-\ linear\\:\\ 0\\.005713819515893198\ \(0\)\
\-\ on\\:\\ 0\\.00570891965587877\ \(0\)\
\-\ etiology\\:\\ 0\\.005705081061042071\ \(0\)\
\-\ bones\\:\\ 0\\.005687748061711478\ \(0\)\
\-\ shortness\\:\\ 0\\.005670603468277876\ \(0\)\
\-\ increase\\:\\ 0\\.005653643228883141\ \(0\)\
\-\ pa\\:\\ 0\\.0056368634209887315\ \(0\)\
\-\ respiratory\\:\\ 0\\.005595678651266829\ \(0\)\
\-\ recommended\\:\\ 0\\.005587569188332415\ \(0\)\
\-\ specific\\:\\ 0\\.00557147428269481\ \(0\)\
\-\ pneumonia\\:\\ 0\\.00557147428269481\ \(0\)\
\-\ same\\:\\ 0\\.005555541954640388\ \(0\)\
\-\ female\\:\\ 0\\.0055418305092991595\ \(0\)\
\-\ line\\:\\ 0\\.005539768952535367\ \(0\)\
\-\ tissues\\:\\ 0\\.005531941209093522\ \(0\)\
\-\ occurs\\:\\ 0\\.005531941209093522\ \(0\)\
\-\ are\\:\\ 0\\.0055120214788466956\ \(0\)\
\-\ where\\:\\ 0\\.005501013020783781\ \(0\)\
\-\ treatment\\:\\ 0\\.005456204919876615\ \(0\)\
\-\ visualized\\:\\ 0\\.005455728942104866\ \(0\)\
\-\ nausea\\:\\ 0\\.005426246082464247\ \(0\)\
\-\ 15\\:\\ 0\\.005375941092281356\ \(0\)\
\-\ use\\:\\ 0\\.005327191033191329\ \(0\)\
\-\ in\\:\\ 0\\.005317315206817097\ \(0\)\
\-\ hypertension\\:\\ 0\\.005313534782807867\ \(0\)\
\-\ minimal\\:\\ 0\\.005306750741957094\ \(0\)\
\-\ system\\:\\ 0\\.005306750741957094\ \(0\)\
\-\ rate\\:\\ 0\\.005253503928195336\ \(0\)\
\-\ pleural\\:\\ 0\\.005233990849642422\ \(0\)\
\-\ previous\\:\\ 0\\.005233990849642422\ \(0\)\
\-\ about\\:\\ 0\\.005195674299848977\ \(0\)\
\-\ process\\:\\ 0\\.005189377736332357\ \(0\)\
\-\ 30\\:\\ 0\\.0051831062089196765\ \(0\)\
\-\ vomiting\\:\\ 0\\.00514599185969224\ \(0\)\
\-\ active\\:\\ 0\\.00514599185969224\ \(0\)\
\-\ 50\\:\\ 0\\.005127757124043856\ \(0\)\
\-\ lungs\\:\\ 0\\.00510376750470075\ \(0\)\
\-\ breath\\:\\ 0\\.005039617599762379\ \(0\)\
\-\ clear\\:\\ 0\\.0049834804623764125\ \(0\)\
\-\ involvement\\:\\ 0\\.004939966335375105\ \(0\)\
\-\ wbc\\:\\ 0\\.0049133672722015955\ \(0\)\
\-\ very\\:\\ 0\\.004892406338260455\ \(0\)\
\-\ being\\:\\ 0\\.004696826461830533\ \(0\)\
\-\ heart\\:\\ 0\\.004683090928878192\ \(0\)\
\-\ was\\:\\ 0\\.004676392060948045\ \(0\)\
\-\ the\\:\\ 0\\.004579234982296754\ \(0\)\
\-\ thickening\\:\\ 0\\.004568808469547873\ \(0\)\
\-\ fever\\:\\ 0\\.004560351145981019\ \(0\)\
\-\ although\\:\\ 0\\.004551938928354264\ \(0\)\
\-\ three\\:\\ 0\\.00454357133808661\ \(0\)\
\-\ size\\:\\ 0\\.004518731658326137\ \(0\)\
\-\ cases\\:\\ 0\\.004490237955806203\ \(0\)\
\-\ unremarkable\\:\\ 0\\.0044622498717382655\ \(0\)\
\-\ injury\\:\\ 0\\.004296858898878234\ \(0\)\
\-\ found\\:\\ 0\\.004247674470744657\ \(0\)\
\-\ any\\:\\ 0\\.004244219295066709\ \(0\)\
\-\ of\\:\\ 0\\.004226478577845007\ \(0\)\
\-\ such\\:\\ 0\\.004213458659054972\ \(0\)\
\-\ days\\:\\ 0\\.004131032012889555\ \(0\)\
\-\ treated\\:\\ 0\\.004034465041141733\ \(0\)\
\-\ from\\:\\ 0\\.0039950653411804805\ \(0\)\
\-\ syndrome\\:\\ 0\\.003854742234597226\ \(0\)\
\-\ appearance\\:\\ 0\\.003854742234597226\ \(0\)\
\-\ she\\:\\ 0\\.0037835743556059497\ \(0\)\
\-\ include\\:\\ 0\\.003780999192476793\ \(0\)\
\-\ ct\\:\\ 0\\.0037706739854638576\ \(0\)\
\-\ secondary\\:\\ 0\\.003768186067048592\ \(0\)\
\-\ however\\:\\ 0\\.0037529464599322876\ \(0\)\
\-\ and\\:\\ 0\\.0036910363951401263\ \(0\)\
\-\ presented\\:\\ 0\\.003674065670382349\ \(0\)\
\-\ lesions\\:\\ 0\\.0036081395999115894\ \(0\)\
\-\ therapy\\:\\ 0\\.0036035343789284115\ \(0\)\
\-\ due\\:\\ 0\\.003596651660808895\ \(0\)\
\-\ common\\:\\ 0\\.0035272353500889544\ \(0\)\
\-\ who\\:\\ 0\\.0035141457557440092\ \(0\)\
\-\ these\\:\\ 0\\.0035076414699650475\ \(0\)\
\-\ for\\:\\ 0\\.003450038558246286\ \(0\)\
\-\ more\\:\\ 0\\.003370940550965562\ \(0\)\
\-\ consistent\\:\\ 0\\.0033048868593552098\ \(0\)\
\-\ increased\\:\\ 0\\.003297294608516807\ \(0\)\
\-\ soft\\:\\ 0\\.003282218870652287\ \(0\)\
\-\ \\;\\:\\ 0\\.003194670644246993\ \(0\)\
\-\ noted\\:\\ 0\\.003194670644246993\ \(0\)\
\-\ without\\:\\ 0\\.003173522344413502\ \(0\)\
\-\ \\%\\:\\ 0\\.003144039484772883\ \(0\)\
\-\ most\\:\\ 0\\.0031117273528834008\ \(0\)\
\-\ \\'s\\:\\ 0\\.0029716823633549605\ \(0\)\
\-\ demonstrates\\:\\ 0\\.002944197478948243\ \(0\)\
\-\ presents\\:\\ 0\\.002753382169570861\ \(0\)\
\-\ also\\:\\ 0\\.002657128696640617\ \(0\)\
\-\ within\\:\\ 0\\.0025711851867288352\ \(0\)\
\-\ male\\:\\ 0\\.0024372327096016926\ \(0\)\
\-\ normal\\:\\ 0\\.002112953398421295\ \(0\)\
\-\ \\.\\:\\ 0\\.002071739488330934\ \(0\)\
\-\ with\\:\\ 0\\.002030040910076951\ \(0\)\
\-\ there\\:\\ 0\\.0020058604991561335\ \(0\)\
\-\ not\\:\\ 0\\.0019476635200976898\ \(0\)\
\-\ history\\:\\ 0\\.0018615371257209516\ \(0\)\
\-\ pain\\:\\ 0\\.0016460696648749758\ \(0\)\
\-\ year\\:\\ 0\\.0015080524751938718\ \(0\)\
\-\ patient\\:\\ 0\\.0013510913736851544\ \(0\)\
